Aratana Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aratana Therapeutics's estimated annual revenue is currently $3.8M per year.(i)
  • Aratana Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Aratana Therapeutics has 19 Employees.(i)
  • Aratana Therapeutics grew their employee count by 6% last year.

Aratana Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.3M519%N/AN/A
#2
$24.7M123-6%N/AN/A
#3
$5.6M28-10%N/AN/A
#4
$26.7M133-4%N/AN/A
#5
$4.4M22-19%N/AN/A
#6
$74.6M3719%N/AN/A
#7
$22.7M1133%N/AN/A
#8
$12.3M858%$20MN/A
#9
$3.8M196%N/AN/A
#10
$5.6M2812%N/AN/A
Add Company

What Is Aratana Therapeutics?

Aratana Therapeutics, Inc. (Nasdaq: PETX) is a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats. Our mission is to successfully develop and deliver best-in-class therapeutics, provide comprehensive service to veterinarians and serve as a collaborator of choice for human and animal health companies. We believe our therapeutics are highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard of care. Our FDA-approved and commercially available therapeutics include: - A prostaglandin receptor antagonist that specifically targets the EP4 receptor to target osteoarthritis pain and inflammation in dogs - A selective ghrelin receptor agonist that mimics ghrelin, the naturally-occurring “hunger hormone,” to stimulate appetite in dogs - A long-acting, local anesthetic that provides up to 72 hours post-operative pain relief following certain surgeries in dogs and cats

keywords:N/A

N/A

Total Funding

19

Number of Employees

$3.8M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aratana Therapeutics News

2022-04-17 - Companion Animal Specialty Drugs Market Analysis Development ...

Bayer, Elanco, Merial, Zoetis, Aratana therapeutics, Beaphar, Henry Schein, Mars, The J.M Smucker Company. Summary of the Report:.

2022-04-17 - Companion Animal Drugs Market Size 2022-2029| Key Players ...

Aratana Therapeutics; Bayer; Boehringer Ingelheim; Ceva Sante Animale; Dechra Pharmaceuticals; Eli Lilly; Merck; Vetoquinol; Virbac; Zoetis.

2022-04-17 - Global Pet Cancer Therapeutics Market 2022 Outlook, Current and ...

Aratana Therapeutics, Inc · AB Science · Boehringer Ingelheim International GmbH · Zenoaq · Morphogenesis, Inc · VetDC, Inc · Karyopharm Therapeutics,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M19-21%N/A
#2
$1.5M2025%N/A
#3
$2.7M24-35%$11.1M
#4
N/A24-4%N/A
#5
$2.4M24-20%N/A